Randomized Trial of Exercise on Lower Extremity Edema After Lymphadenectomy in Gynecologic Cancer

Sponsor
National Cancer Center, Korea (Other)
Overall Status
Unknown status
CT.gov ID
NCT01849224
Collaborator
(none)
148
1
2
31
4.8

Study Details

Study Description

Brief Summary

The primary outcome is the change in lower extremity edema-related symptoms. Secondary outcomes include the compliance rate of management guidelines for lower extremity edema, the performance rate for pelvic and lower extremity exercise.

Condition or Disease Intervention/Treatment Phase
  • Other: Pelvic and lower extremity exercise
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
148 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Trial of Pelvic and Lower Extremity Exercise in Patients Who Underwent Pelvic Lymphadenectomy With Lower Extremity Edema-related Symptoms
Study Start Date :
May 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2015
Anticipated Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pelvic and lower extremity exercise

Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.

Other: Pelvic and lower extremity exercise

No Intervention: Control

Control group will be educated the guidelines for prevention and early detection of lower extremity edema

Outcome Measures

Primary Outcome Measures

  1. Change in lower extremity edema-related symptoms after pelvic and lower extremities exercise [1 year after randomization]

Secondary Outcome Measures

  1. the compliance rate of management guidelines for lower extremity edema, the performance rate for pelvic and lower extremity exercise [1 year after randomization]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • More than 18 years of age

  • Patients who underwent pelvic lymphadenectomy

  • Patients with suspicious pelvic cancer who finished active treatments such as chemotherapy, radiotherapy or surgery. The interval between the time of randomization and the end of the treatment should be more than 2 weeks.

  • The patient is able to understand the study and is willing to give written informed consent to the study

  • patient with edema-related symptoms such as leg heaviness, distension, tightness, pain, limited movement, or weakness etc.

Exclusion Criteria:
  • Severe systemic diseases causing peripheral edema, including renal disease

  • Severe or uncontrolled cardiopulmonary disease, including implantable device such as a pacemaker

  • Acute superficial or deep vein thrombosis

  • Previous major surgery for lower extremities, including metallic surgical implant

  • Local infection in the lower extremities

  • Auto-immunological disorders or vasculitis

  • Use of systemic corticosteroids

  • Pregnant or currently breastfeeding

  • Alcohol or drug abuse

  • Uncontrolled diabetes

Contacts and Locations

Locations

Site City State Country Postal Code
1 Myong Cheol Lim Goyang-si Gyeonggi-do Korea, Republic of 410-769

Sponsors and Collaborators

  • National Cancer Center, Korea

Investigators

  • Principal Investigator: Lim Myong Cheol, MD,PhD, National Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Myong Cheol Lim, Senior researcher, National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT01849224
Other Study ID Numbers:
  • NCCNCS-13-723
First Posted:
May 8, 2013
Last Update Posted:
Jul 16, 2013
Last Verified:
Jul 1, 2013
Keywords provided by Myong Cheol Lim, Senior researcher, National Cancer Center, Korea
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2013